TC
RCUS icon

Truvestments Capital’s Arcus Biosciences RCUS Stock Holding History

Truvestments Capital’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.07K Buy
+197
New +$4.87K ﹤0.01% 866

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Truvestments Capital's RCUS Position: Q2 2026 in Review

Truvestments Capital opened a new position in Arcus Biosciences (RCUS) in Q2 2026: 197 shares worth $6.07K. The stake represents ﹤0.01% of the portfolio and ranks #866 among its holdings.

229 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

  • Truvestments Capital held 197 shares of Arcus Biosciences worth $6.07K as of Q2 2026.
  • Arcus Biosciences was a new Truvestments Capital position in Q2 2026.
  • Arcus Biosciences made up ﹤0.01% of Truvestments Capital's portfolio in Q2 2026, its #866 holding.
  • 229 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on Truvestments Capital's 13F filing for Q2 2026, filed 12 Aug 2026.